Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform
PR89505
PROVIDENCE, R.I., May 14, 2021 /PRNewswire=KYODO JBN/ --
EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multi–step
screening of neoantigens' HLA and TCR–interfaces improves prediction of
survival" in Scientific Reports (
). This study demonstrates a superior method of survival analysis for cancer
patients using EVT's Ancer platform. EVT spun-off from EpiVax, Inc. in 2017 to
apply EpiVax tools to clinical research.
Logo - https://mma.prnewswire.com/media/1509818/EpiVax_Therapeutics__Logo.jpg
Built on validated in silico tools EpiMatrix (
) and JanusMatrix (
), Ancer analyzes individual cancer mutanomes to define the presence of T cell
epitopes likely to be immunogenic. The concept behind Ancer is that the
presence of a mutation alone is not sufficient to generate a protective immune
response, but that the differences present between the natural (human genome)
sequence and the mutated sequence at the face of the epitope that is
identifiable to T cells (the TCR-face) should be accounted for when creating
precision cancer vaccines and predicting survival outcomes for cancer patients.
This is because some mutations create self-like epitopes and can be tolerated
by the immune system.
Researchers compared three approaches to analyzing cancer mutanomes and
evaluated their ability to predict patient outcomes. Ancer, the best performing
method, improved the differentiation of patients that did poorly from those who
did well, accurately predicting survival outcome nearly 6 years longer as
compared to other approaches, which only predicted as far as 3 years. This
study has important consequences in our ability to identify patients with a
high risk of tumor progression and early mortality based on their tumor genome.
On study implications, Dr. Randy Sweis of the University of Chicago stated,
"These results suggest that defining the number of true neoepitopes using Ancer
may represent a novel prognostic or predictive biomarker for cancer patients."
Dr. Annie De Groot, EVT co-founder, suggested "In addition to biomarker
identification, using Ancer novel precision vaccines for individual cancer
patients offers major advantages compared to other approaches, since Ancer
prioritizes truly immunogenic CD8 and CD4 neoepitopes, while removing self-like
or inhibitory neoepitopes."
Visit Scientific Reports for the free full-text. (
)
About EVT:
EVT employs a world-leading technology, developed over 23 years by EpiVax (
https://c212.net/c/link/?t=0&l=en&o=3162949-1&h=2277679495&u=http%3A%2F%2Fwww.epivax.com%2F&a=EpiVax
), to design vaccines that aim to activate the body's T cells to cure or
prevent disease in the host. EVT's pipeline includes a COVID-19 vaccine and a
personalized bladder cancer vaccine (
).
Interested investors can evaluate EVT on RedCrow here (
).
Press Contact:
Katie Porter, Business Development Manager
EpiVax
kporter@epivax.com
SOURCE: EpiVax Therapeutics, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。